Biomarkers, C-reactive proteins and statins in acute coronary syndromes

Fundamental and Clinical Pharmacology

Volumn 21, Issue SUPPL. 2, 2007, Pages 31-33

  Ray, Kausik K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Acute coronary syndromes; Biomarkers; Endothelial function; Inflammation; Statins

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; NEOPTERIN; PHOSPHOLIPASE A2; PRAVASTATIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR ADHESION MOLECULE-1; NATRIURETIC PEPTIDE, BRAIN; NEOPTERIN;

EID: 36248983272     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00537.x     Document Type: Review

References (10)

1. Naghavi M., Libby P., Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 108 1664 1672.
2. Naghavi M., Libby P., Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 108 1772 1778.
3. Sabatine M.S., Morrow D.A., de Lemos J.A. et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation (2002) 105 1760 1763.
4. Ray K.K., Cannon C.P. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J. Thromb. Thrombolysis. (2004) 18 89 101.
5. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 286 64 70.
6. Ridker P.M., Cannon C.P., Morrow D. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. (2005) 352 20 28.
7. O'Donoghue M., Morrow D.A., Sabatine M.S. et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation (2006) 113 1745 1752.
8. de Lemos J.A., Morrow D.A., Bentley J.H. et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. (2001) 345 1014 1021.
9. Ray K.K., Morrow D.A., Sabatine M.S. et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation (2007) 115 3071 3078.
10. Kinlay S., Schwartz G.G., Olsson A.G. et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation (2004) 110 386 391.